Clinical Trials in Minneapolis

Showing 5361-5380 of 14,456 trials

Retrospective Evaluation of SuperSaturated Oxygen (SSO2) Therapy Clinical Utility

NCT05949515

The purpose of this multicenter study is to assess the impact of SSO2 treatment on clinical outcomes and left ventricular function in patients following acute ST-segment elevation myocardial infarction (STEMI).

Acute ST Segment Elevation Myocardial Infarction

Cardiovascular Research Foundation, New York403 participantsStarted Jul 2023

Miami, Florida, United States • Naples, Florida, United States • Dearborn, Michigan, United States +5 more locations

COMPLETEDPhase 3< 1 mile

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

NCT02782741

Primary Objective: To determine the effect of avalglucosidase alfa treatment on respiratory muscle strength measured by percent (%) predicted forced vital capacity (FVC) in the upright position, as compared to alglucosidase alfa. Secondary Objective: To determine the safety and effect of avalglucosidase alfa treatment on functional endurance (6-minute walk test, inspiratory muscle strength (maximum inspiratory pressure), expiratory muscle strength (maximum expiratory pressure), lower extremity muscle strength (hand-held dynamometry), motor function (Quick Motor Function Test), and health-related quality of life (Short Form-12).

Glycogen Storage Disease Type II;Pompe's Disease

Genzyme, a Sanofi Company101 participantsStarted Nov 2016

Phoenix, Arizona, United States • Los Angeles, California, United States • Orange, California, United States +66 more locations

Retrospective Evaluation of SuperSaturated Oxygen (SSO2) Therapy Clinical Utility

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

Find Trials by Condition in Minneapolis

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

REDAPT Retrospective-Prospective Modular Stem Study

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients